Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types
PPARγ is a therapeutic target that has been exploited for treatment of type II diabetes mellitus (T2DM) with agonist drugs. Since PPARγ is expressed by many hematopoietic, mesodermal and epithelial cancers, agonist drugs were tested and shown to have both preclinical and clinical anticancer activit...
Saved in:
Main Authors: | Jack D. Burton, David M. Goldenberg, Rosalyn D. Blumenthal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2008-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2008/494161 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease
by: Jean Dallongeville, et al.
Published: (2009-01-01) -
Role of Peroxisome Proliferator-Activated Receptor Gamma and Its Ligands in the Treatment of Hematological Malignancies
by: Richard P. Phipps, et al.
Published: (2008-01-01) -
Molecular docking of ferulic acid, bakuchiol and niazirin on peroxisome proliferator-activated receptor gamma (PPAR-γ) as anti-diabetic agents
by: Anjar Hermadi Saputro, et al.
Published: (2024-08-01) -
Peroxisome Proliferator-Activated Receptors in Lung Cancer
by: Venkateshwar G. Keshamouni, et al.
Published: (2007-01-01) -
Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy
by: Shinji Kume, et al.
Published: (2008-01-01)